NASDAQ:SIGA

SIGA Technologies Competitors

$7.10

+0.04 (+0.57 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$7.01

Now: $7.10▼

$7.18

50-Day Range

$6.32

MA: $6.65▼

$7.15

52-Week Range

$5.25

Now: $7.10▼

$8.10

Volume282,283 shs

Average Volume267,333 shs

Market Capitalization$544.91 million

P/E Ratio17.75

Dividend YieldN/A

Beta0.53

SIGA Technologies (NASDAQ:SIGA) Vs. IGMS, RVNC, DRNA, AXSM, NGM, and MORF

Should you be buying SIGA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to SIGA Technologies, including IGM Biosciences (IGMS), Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), and Morphic (MORF).

SIGA Technologies vs. IGM Biosciences Stock

IGM Biosciences (NASDAQ:IGMS) and SIGA Technologies (NASDAQ:SIGA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Risk & Volatility

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are owned by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are owned by institutional investors. 79.3% of IGM Biosciences shares are owned by insiders. Comparatively, 3.9% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares IGM Biosciences and SIGA Technologies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IGM Biosciences	N/A	N/A	$-43,130,000.00	($4.80)	-14.27
SIGA Technologies	$26.74 million	20.38	$-7,240,000.00	N/A	N/A

SIGA Technologies has higher revenue and earnings than IGM Biosciences.

Analyst Ratings

This is a breakdown of current recommendations and price targets for IGM Biosciences and SIGA Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IGM Biosciences	0	1	6	0	2.86
SIGA Technologies	0	0	0	0	N/A

IGM Biosciences currently has a consensus target price of $98.8750, indicating a potential upside of 44.36%. Given IGM Biosciences' higher possible upside, equities analysts clearly believe IGM Biosciences is more favorable than SIGA Technologies.

Profitability

This table compares IGM Biosciences and SIGA Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IGM Biosciences	N/A	-33.30%	-30.28%
SIGA Technologies	34.62%	37.31%	25.33%

Summary

SIGA Technologies beats IGM Biosciences on 7 of the 11 factors compared between the two stocks.

SIGA Technologies vs. Revance Therapeutics Stock

Revance Therapeutics (NASDAQ:RVNC) and SIGA Technologies (NASDAQ:SIGA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Revance Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

74.4% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by insiders. Comparatively, 3.9% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Revance Therapeutics and SIGA Technologies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revance Therapeutics	$410,000.00	4,897.57	$-159,430,000.00	($3.67)	-7.66
SIGA Technologies	$26.74 million	20.38	$-7,240,000.00	N/A	N/A

SIGA Technologies has higher revenue and earnings than Revance Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Revance Therapeutics and SIGA Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revance Therapeutics	0	0	5	0	3.00
SIGA Technologies	0	0	0	0	N/A

Revance Therapeutics currently has a consensus target price of $36.40, indicating a potential upside of 29.40%. Given Revance Therapeutics' higher possible upside, research analysts clearly believe Revance Therapeutics is more favorable than SIGA Technologies.

Profitability

This table compares Revance Therapeutics and SIGA Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revance Therapeutics	-5,818.87%	-85.72%	-44.85%
SIGA Technologies	34.62%	37.31%	25.33%

SIGA Technologies vs. Dicerna Pharmaceuticals Stock

Dicerna Pharmaceuticals (NASDAQ:DRNA) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 3.9% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and SIGA Technologies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dicerna Pharmaceuticals	$23.90 million	83.31	$-120,460,000.00	($1.76)	-14.82
SIGA Technologies	$26.74 million	20.38	$-7,240,000.00	N/A	N/A

SIGA Technologies has higher revenue and earnings than Dicerna Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Dicerna Pharmaceuticals and SIGA Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dicerna Pharmaceuticals	0	0	6	0	3.00
SIGA Technologies	0	0	0	0	N/A

Dicerna Pharmaceuticals currently has a consensus target price of $37.8333, indicating a potential upside of 45.01%. Given Dicerna Pharmaceuticals' higher possible upside, research analysts clearly believe Dicerna Pharmaceuticals is more favorable than SIGA Technologies.

Profitability

This table compares Dicerna Pharmaceuticals and SIGA Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dicerna Pharmaceuticals	-88.81%	-71.72%	-16.60%
SIGA Technologies	34.62%	37.31%	25.33%

SIGA Technologies vs. Axsome Therapeutics Stock

Axsome Therapeutics (NASDAQ:AXSM) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Axsome Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Earnings and Valuation

This table compares Axsome Therapeutics and SIGA Technologies' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	N/A	N/A	$-68,350,000.00	($2.01)	-26.36
SIGA Technologies	$26.74 million	20.38	$-7,240,000.00	N/A	N/A

SIGA Technologies has higher revenue and earnings than Axsome Therapeutics.

Institutional and Insider Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Comparatively, 3.9% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Axsome Therapeutics and SIGA Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	N/A	-62.33%	-47.87%
SIGA Technologies	34.62%	37.31%	25.33%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Axsome Therapeutics and SIGA Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1	0	11	0	2.83
SIGA Technologies	0	0	0	0	N/A

Axsome Therapeutics currently has a consensus target price of $146.90, indicating a potential upside of 177.22%. Given Axsome Therapeutics' higher possible upside, research analysts clearly believe Axsome Therapeutics is more favorable than SIGA Technologies.

Summary

SIGA Technologies beats Axsome Therapeutics on 6 of the 11 factors compared between the two stocks.

SIGA Technologies vs. NGM Biopharmaceuticals Stock

NGM Biopharmaceuticals (NASDAQ:NGM) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Volatility & Risk

NGM Biopharmaceuticals has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares NGM Biopharmaceuticals and SIGA Technologies' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NGM Biopharmaceuticals	$103.54 million	18.84	$-42,790,000.00	($0.85)	-29.92
SIGA Technologies	$26.74 million	20.38	$-7,240,000.00	N/A	N/A

SIGA Technologies has lower revenue, but higher earnings than NGM Biopharmaceuticals.

Institutional & Insider Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NGM Biopharmaceuticals and SIGA Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NGM Biopharmaceuticals	-91.64%	-29.47%	-25.58%
SIGA Technologies	34.62%	37.31%	25.33%

Analyst Ratings

This is a summary of current ratings and price targets for NGM Biopharmaceuticals and SIGA Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NGM Biopharmaceuticals	0	0	5	2	3.29
SIGA Technologies	0	0	0	0	N/A

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, indicating a potential upside of 53.80%. Given NGM Biopharmaceuticals' higher possible upside, analysts plainly believe NGM Biopharmaceuticals is more favorable than SIGA Technologies.

Summary

NGM Biopharmaceuticals beats SIGA Technologies on 7 of the 13 factors compared between the two stocks.

SIGA Technologies vs. Morphic Stock

Morphic (NASDAQ:MORF) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Volatility & Risk

Morphic has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares Morphic and SIGA Technologies' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Morphic	$16.98 million	113.42	$-43,330,000.00	($2.69)	-22.06
SIGA Technologies	$26.74 million	20.38	$-7,240,000.00	N/A	N/A

SIGA Technologies has higher revenue and earnings than Morphic.

Institutional & Insider Ownership

61.5% of Morphic shares are held by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are held by institutional investors. 39.5% of Morphic shares are held by company insiders. Comparatively, 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Morphic and SIGA Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Morphic	N/A	-36.62%	-20.69%
SIGA Technologies	34.62%	37.31%	25.33%

Analyst Ratings

This is a summary of current ratings and price targets for Morphic and SIGA Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Morphic	0	0	2	0	3.00
SIGA Technologies	0	0	0	0	N/A

Morphic presently has a consensus target price of $63.3333, indicating a potential upside of 6.71%. Given Morphic's higher possible upside, analysts plainly believe Morphic is more favorable than SIGA Technologies.